Spark Wins First Ever Gene Therapy for Inherited Disease

Dec 20, 2017

The FDA has approved Spark Therapeutics’ treatment for a rare form of blindness — the first ever approved a gene therapy for an inherited disease.

Spark has yet to announced a price for the one-time treatment, but analysts predict that it will cost around $1 million

Spark’s drug, Luxturna, treats inherited retinal disease caused by defects in a gene known as RPE65 — a condition that affects between 1,000 and 2,000 people in the United States.

Read the Reuters coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments